A randomized, double-blind, placebo-controlled, cross-over trial to investigate the effect of GSK189075 [remogliflozin etabonate] on cardiac repolarization as compared to placebo and a single dose of moxifloxacin in healthy adult subjects.
Phase of Trial: Phase I
Latest Information Update: 16 Mar 2012
At a glance
- Drugs Moxifloxacin; Remogliflozin etabonate
- Indications Bacterial infections; Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 19 Jun 2008 Status changed from recruiting to completed according to clinicaltrials.gov.
- 02 Nov 2007 Status changed from initiated to recruiting.
- 02 Oct 2007 New trial record.